8-K: CannaPharmaRX Appoints Barzily & Co. as New Independent Auditor

CannaPharmaRX, Inc. has engaged Barzily & Co. as its new independent registered public accounting firm, effective November 29, 2024.

Summary

• CannaPharmaRX, Inc. has appointed Barzily & Co. as their new independent registered public accounting firm.
• This change is effective as of November 29, 2024.
• Barzily will be responsible for auditing the company's financial statements for the fiscal year ending December 31, 2024.
• The company has not consulted with Barzily on any accounting or auditing matters prior to this appointment.

Sentiment

Score: 7

Explanation: The document is a routine announcement of an auditor change, which is generally neutral to slightly positive as it indicates compliance and governance. There are no indications of any issues.

Positives

• The appointment of a new auditor can bring a fresh perspective to the company's financial reporting.
• Engaging a new auditor is a standard practice and can enhance investor confidence.

Risks

• The transition to a new auditor could potentially introduce some short-term challenges in the audit process.
• There is a risk of delays or unexpected issues during the audit process with a new firm.

Future Outlook

The company will be working with Barzily & Co. to complete the audit for the fiscal year ending December 31, 2024.

Management Comments

• Rick Orman, Chairman of CannaPharmaRX, signed the report on behalf of the company.

Industry Context

The appointment of a new auditor is a routine event for publicly traded companies and is part of maintaining compliance with regulatory requirements.

Comparison to Industry Standards

• Changing auditors is a common practice among public companies, often done to ensure independence and fresh perspectives on financial reporting.
• Many companies, such as those listed on the OTC Markets like CannaPharmaRX, regularly change auditors to maintain compliance and best practices.
• The process of engaging a new auditor typically involves a review of the firm's qualifications and independence, which CannaPharmaRX appears to have followed.

Stakeholder Impact

• Shareholders will be interested in the new auditor's assessment of the company's financial statements.
• The change in auditor is not expected to have a significant impact on employees, customers, or suppliers.

Next Steps

• Barzily & Co. will begin the audit of CannaPharmaRX's financial statements for the fiscal year ending December 31, 2024.

Key Dates

Keywords

auditor, accounting, financial reporting, Barzily & Co., CannaPharmaRX, independent auditor